(SeaPRwire) –
By: Robert Kensington
Dermavon is not merely collecting regulatory approvals in mainland China. The subsidiary of China Medical System Holdings Limited is building a balance sheet for its public listing. The company is preparing for a spin-off listing on the Main Board of The Stock Exchange of Hong Kong Limited. It needs to demonstrate rapid revenue trajectory to private equity backers and public markets. In January 2026, Lumirix received its initial approval from the National Medical Products Administration for vitiligo. That made it the first approved topical JAK inhibitor in China. On September 2, 2026, the agency granted New Drug Application approval for its second indication. The official drug registration certificate was issued on September 3, 2026. This approval covers mild to moderate atopic dermatitis in non-immunocompromised patients two years of age and older. The Center for Drug Evaluation processed the application through its Priority Review List under pediatric drug qualifications. The swift approval window highlights Dermavon’s intent. The corporate entity wants to lock in commercial territory ahead of investor roadshows.
The official narrative presents this regulatory milestone as a major clinical victory for pediatric dermatology. Dermavon points to robust local Phase III trial data to validate its therapeutic claims. In the primary endpoint at week eight, 63.0% of Lumirix patients achieved an Investigator’s Global Assessment score of 0 or 1 with at least a two-grade reduction from baseline. The placebo group recorded only 9.2%. For the key secondary endpoint, 78.0% of Lumirix patients achieved at least a 75% improvement in the Eczema Area and Severity Index score at week eight. The placebo cohort reached just 15.4%. Most adverse events were mild or moderate, with no study drug discontinuations. The commercial reality behind these numbers involves capturing a massive patient volume. Data from CIC Report indicates China had over 54 million atopic dermatitis patients in 2024. Mild to moderate cases represent 98% of this total, equaling roughly 52.5 million individuals. Traditional prescription therapies like topical corticosteroids and calcineurin inhibitors carry compliance limits and safety concerns. Dermavon is using this non-steroidal label expansion to displace legacy prescription creams across pediatric outpatient clinics.
Dermavon frames this approval as part of a integrated treatment portfolio. The corporate pipeline includes topical Lumirix for mild to moderate cases and injectable Comekibart under NDA review for moderate to severe cases. It also features oral CMS-D001 in Phase II clinical trials and the Heling product line for daily skin care. Dermavon plans to cross-sell these products alongside marketed items like ILUMETRI and Hirudoid. Behind this brand strategy lies the financial architecture of international licensing deals. Dermavon signed an exclusive Collaboration and License Agreement with Incyte on December 2, 2022. The agreement secured development and commercial rights for ruxolitinib phosphate cream across Mainland China, Hong Kong, Macau, Taiwan, and eleven Southeast Asian countries. Dermavon sublicensed rights outside Mainland China back to parent company China Medical System Holdings Limited. Incyte markets the formulation in Western regions as Opzelura. Dermavon must maximize regional prescription volume to cover licensing terms and support its standalone valuation. Leveraging existing field sales representatives across hospital networks is a tactical necessity to harvest cash flow before generic small-molecule alternatives gain regulatory traction.
Dermavon’s expanded label will disrupt traditional dermatological prescribing patterns across Chinese hospitals. Expect legacy topical steroid manufacturers to suffer immediate market share loss as clinical guidelines pivot toward targeted, non-steroidal JAK inhibitors.
Author bio: Robert Kensington, an overseas entrepreneurial veteran with decades of experience in real-economy industrial investment and expansion.